Kidney and liver
Vasopressin V2 receptor antagonists (tolvaptan)
Drugs that block the action of antidiuretic hormone on the collecting duct: tolvaptan slows cyst growth and the decline of kidney function in rapidly progressing polycystic kidney disease, and corrects some hyponatraemia.
Mécanisme d’action
- Vasopressin acting on V2 receptors raises cyclic AMP in collecting duct cells, inserting aquaporin-2 water channels.
- In polycystic kidney disease, cyclic AMP also drives cyst-lining cells to proliferate and secrete fluid.
- Tolvaptan blocks V2 receptors: free water is excreted (aquaresis) and cyst growth slows.
Cibles moléculaires
- Vasopressin V2 receptor (collecting duct): Antagonist
Médicaments : Vasopressin V2 receptor antagonists (tolvaptan)
V2-selective
- Tolvaptan (By mouth; liver tests are monitored.)
V1a and V2
- Conivaptan (Intravenous, V1a and V2; for hyponatraemia.)
Indications thérapeutiques
- Autosomal dominant polycystic kidney disease at risk of rapid progression
- Hyponatraemia from SIADH or heart failure
Maladies traitées
Effets indésirables
- Thirst, frequent urination and nocturia
- Liver injury
- Too rapid a rise in sodium, which can cause osmotic demyelination
Contre-indications selon le terrain
- Liver cirrhosis (Contre-indiqué): Tolvaptan can cause serious liver injury.
- Inability to sense or respond to thirst (Contre-indiqué): Free water loss causes dehydration and hypernatraemia.
- Taking strong CYP3A4 inhibitors (Avec précaution): Levels rise sharply.
Sujets liés
Rédigé d’après
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 15, Diuretic Agents, ADH antagonists
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 37, Hypothalamic & Pituitary Hormones, Vasopressin antagonists
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.